

Press Release

NeuroVive Pharmaceutical AB (publ), 556595-6538
22 April 2020 11:15:00 CEST - Lund, Sweden



NeuroVive's Board Members and Senior Executives subscribe to shares in the ongoing rights issue

In the ongoing rights issue in NeuroVive, the Board and Senior Executives have undertaken to subscribe for at least 446,176 shares.

The subscription period will continue until 29 April, 2020, and is open to both existing and new investors.

Read more about the rights issue at <http://www.neurovive.com/rightsissue2020ld/>.

Prospectus (in Swedish), containing full terms and conditions, as well as application forms are available on NeuroVive's website www.neurovive.com, and on Erik Penser Bank's website www.penser.se.

For more information, please contact:

Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

info@neurovive.com, www.neurovive.com

For news subscription, please visit <http://www.neurovive.com/press-releases/subscription-page/>

Follow us on [LinkedIn](#)

Subscribe to our [YouTube channel](#)

About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH. NeuroVive's ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive's NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTC Market's Pink Open market in the US (OTC: NEVPF).

Attachments

[NeuroVive's Board Members and Senior Executives subscribe to shares in the ongoing rights issue](#)

NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets' Pink Open market (ticker symbol NEVPF) in the US. Investors can find Real-Time quotes and market information for the company at www.otcmarkets.com/stock/NEVPF/quote.